Table 3.
Final diagnosis of the adnexal masses according to the reference standard for the whole cohort and the random subset
| Final diagnosis | Whole cohort (n = 350) | Random subset (n = 121) |
|---|---|---|
| Normal ovary, n (%) | 6 (1.7)* | 2 (1.6) |
| Benign disease, n (%) | 291 (83.1) | 99 (81.8) |
| Ovarian | ||
| Benign Brenner tumor | 2 (0.5) | 0 (0.0) |
| Benign germ cell tumor | 84 (24.0) | 32 (26.4) |
| Benign ovarian cyst | 28 (8.0) | 14 (11.5) |
| Benign stromal tumor | 29 (8.2) | 8 (6.6) |
| Cystadenoma | 53 (15.1) | 14 (11.5) |
| Cystadenofibroma | 16 (4.5) | 5 (4.1) |
| Endometrioma | 68 (19.4) | 22 (18.1) |
| Functional cyst | 3 (0.8) | 1 (0.8) |
| TOA/inflammation | 4 (1.1) | 3 (2.4) |
| Non-ovarian | ||
| Benign non-ovarian cyst# | 2 (0.5) | 0 (0.0) |
| Leiomyoma | 2 (0.5) | 0 (0.0) |
| Borderline disease, n (%) | 14 (4.0) | 5 (4.1) |
| Ovarian | ||
| Serous borderline | 9 (2.5) | 3 (2.4) |
| Mucinous borderline | 5 (1.4) | 2 (1.6) |
| Malignant disease, n (%) | 39 (11.1) | 15 (12.3) |
| Ovarian | ||
| Clear cell carcinoma | 6 (1.7) | 2 (1.6) |
| Endometrioid carcinoma | 5 (1.4) | 2 (1.6) |
| Serous carcinoma | 16 (4.5) | 6 (4.9) |
| Mucinous carcinoma | 1 (0.2) | 0 (0.0) |
| Transitional cell carcinoma | 2 (0.5) | 0 (0.0) |
| Malignant germ cell tumor | 3 (0.8) | 3 (2.4) |
| Malignant sex-cord stromal tumor | 2 (0.5) | 0 (0.0) |
| Metastasis§ | 2 (0.5) | 0 (0.0) |
| Non-ovarian | ||
| Other (i.e. lymphoma) | 2 (0.5) | 2 (1.6) |
TOA tubo-ovarian abscess
*Unless otherwise specified, data are numbers of masses, with percentages in parenthesis
#Benign non-ovarian cyst refers to paraovarian cyst or peritoneal inclusion cyst
§Two adnexal masses which were scored as primary adnexal masses resulted as metastases after histopathological assessment